📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL-286, a novel retinoic acid receptor-ß agonist for treatment of spinal cord injury, in male healthy participants. (2023)

First Author: Goncalves MB

Attributed to: A phase 1 trial of a retinoic acid receptor beta agonist for the treatment of spinal cord injury funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bcp.15854

PubMed Identifier: 37452623

Publication URI: http://europepmc.org/abstract/MED/37452623

Type: Journal Article/Review

Volume: 89

Parent Publication: British journal of clinical pharmacology

Issue: 12

ISSN: 0306-5251